Project Grant R01CA287116
- Federal Grant Award Summary The National Cancer Institute awarded a $663,340 Project Grant to the University of California, Berkeley on August 27, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The research will elucidate mechanisms by which local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer (NK) cells and CD4 T cells to control tumors that have...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $618,928 Project Grant to The Regents of the University of California, doing business as University of California, Berkeley, under the Cancer Biology Research program (CFDA 93.396) on June 9, 2025. The award funds a five-year research initiative through May 31, 2030, investigating the immunosuppressive mechanisms of intratumoral regulatory T cells (Tregs) to advance immune-based cancer therapies. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant totaling $650,597 to the University of California, San Diego, effective April 1, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). The research project investigates the role of B-cells in generating durable complete responses to checkpoint blockade immunotherapy in head and neck squamous cell carcinoma patients. The study addresses the observation that while response rates...
- Federal Grant Award Summary The National Cancer Institute awarded University of California, San Diego a $699,929 Project Grant on June 20, 2025, under the Cancer Treatment Research program (CFDA 93.395) to enhance immunotherapy response in human papillomavirus negative head and neck squamous cell carcinoma (HPV-HNSCC). The project, which extends through May 31, 2030, focuses on improving dendritic cell (DC) migration to draining sentinel lymph nodes to enhance the efficacy of programmed...
- Federal Project Grant Award Summary The University of California, San Francisco received a $677,787 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 26, 2025, with a completion date of July 31, 2030. The award funds research to identify and characterize Aire-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion and to develop therapeutic strategies targeting this...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of California, Irvine a $586,364 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective April 7, 2026, with completion targeted for March 31, 2031. This research initiative investigates Type 1 Innate Lymphoid Cells (ILC1s), including Natural Killer (NK) cells and related immune cells, to elucidate their mechanisms of action and therapeutic potential against Acute Myeloid Leukemia (AML)....
- Federal Grant Award Summary The National Cancer Institute awarded the University of Illinois a $386,279 Project Grant on July 10, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop innovative immunotherapy screening capabilities. The grant funds the creation of a microfluidic device cassette and associated functional immune assay protocols designed to enable personalized immunotherapy screening directly on core needle biopsies from cancer patients. This...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Beckman Research Institute of the City of Hope a Project Grant totaling $733,864 under the Cancer Biology Research program (CFDA 93.396) for the period June 1, 2026 through May 31, 2031. This award funds fundamental research aimed at identifying and characterizing stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR), a critical mechanism of tumor surveillance and...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Biology Research program (CFDA 93.396), awarded a $661,721 Project Grant to the University of California, San Diego, with an award date of April 1, 2026, and a completion date of March 31, 2031. This five-year research initiative focuses on systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The project will utilize novel high-throughput...
The National Cancer Institute awarded University of California, Irvine a $648,626 Project Grant on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI). The research, which runs through March 31, 2031, addresses a critical gap in cancer immunotherapy by examining why PD-1 (programmed death receptor 1) blockade and dual checkpoint inhibitor combinations fail in most cancer patients despite showing durable benefits in approximately 40% of metastatic melanoma cases and select other cancer types. The primary deliverables include scientific research outputs focused on understanding how PD-1 blockade modulates T regulatory cell (Treg) biology and the spatial organization of the tumor microenvironment. Specifically, the project will employ functional intravital microscopy and cell communication analysis of RNA sequencing data to identify signaling pathways that support Treg proliferation and function in response to checkpoint inhibitor therapy. The research outputs are intended to provide mechanistic insights that will enable researchers to disable immunosuppressive pathways and enhance the therapeutic efficacy of cancer immunotherapy for broader patient populations across multiple cancer types.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $648.6k | 4/6/26 |